F. Alzoughool, R. Abdelqader, S. Abumweis, A. Al-Bashaireh, Y. Aljawarneh, M. Alzghool, L. Alanagreh

Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa, Jordan. foad@hu.edu.jo

OBJECTIVE: The recently discovered protein adropin is a highly conserved polypeptide that plays critical functions in energy homeostasis, metabolic processes, fat metabolism, and insulin resistance. On the other hand, non-alcoholic fatty liver disease (NAFLD) is a medical condition that causes the buildup of fat in the liver cells in individuals who consume little or no alcohol. The frequency of NAFLD is rising globally, and it is frequently linked to obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Therefore, this study evaluates the association between adropin levels and insulin resistance in individuals with and without NAFLD.

MATERIALS AND METHODS: Data from Scopus, Science Direct, and PubMed were searched between January 1, 2012, and February 18, 2024, using precise terms and stated criteria. Comprehensive Meta-Analysis V. 2 (Biostat, Englewood, NJ, USA) was used for data analysis, and Random-effect models were used to estimate the pooled mean differences with 95% CIs of adropin level, insulin level, and homeostatic model assessment for insulin resistance (HOMA-IR) associated with the exposures of interest.

RESULTS: Our results revealed that adropin blood levels are significantly reduced in NAFLD patients compared to control individuals. The mean difference in adropin blood levels was 2.391 ng/ml with a 95% CI of 1.127 to 3.656 with I2 99.6. on the other hand, insulin resistance was significantly higher in NAFLD compared to controls (MD: -1.668, 95% CI: -2.333 to -1.002, I2=86%).

CONCLUSIONS: Our findings reveal that adropin levels are significantly greater in healthy controls than in NAFLD patients, suggesting that adropin may have a preventative effect on NAFLD. This meta-analysis highlights how closely adropin and insulin resistance interact in non-alcoholic fatty liver disease. Also, it may open the door to new diagnostic tools and therapeutic modalities.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

F. Alzoughool, R. Abdelqader, S. Abumweis, A. Al-Bashaireh, Y. Aljawarneh, M. Alzghool, L. Alanagreh
Evaluation of adropin level and insulin resistance in non-alcoholic fatty liver patients: a meta-analysis of studies

Eur Rev Med Pharmacol Sci
Year: 2024
Vol. 28 - N. 21
Pages: 4507-4514
DOI: 10.26355/eurrev_202411_36909